Skip to content
中文产业新闻评分21Chinese source

诺和诺德启动zenagamtide（司美格鲁肽）I期临床试验，针对2型糖尿病、肥胖及超重人群

10月魔方TOP药企动态播报 | Novo Nordisk-zenagamtide,司美格鲁肽启动一项 针对2型糖尿病,肥胖,超重的Phase I临床试验

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.